Flexion Therapeutics

Flexion Therapeutics is an American biopharmaceutical company based in Burlington, Massachusetts that is focused on the discovery, development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the most common form of arthritis.[1][2][3]

Flexion Therapeutics, Inc.
TypePublic
Traded as
Nasdaq: FLXN
Russell 2000 Component
IndustryPharmaceuticals
Founded2007
HeadquartersBurlington, MA
WebsiteFlexion Therapeutics

Flexion was founded around 2007 by two former Eli Lilly & Co. executives, Michael Clayman, MD, and Neil Bodick, MD, PhD., and it went public in 2014.[4] The company has five core values which form the fabric of the organization: focus, ingenuity, tenacity, transparency and fun. Flexion was named one of the best places to work, in the Boston area, by the Boston Business Journal in 2017, 2018 and 2019,[5] and it was named one of the Top Places to Work in Massachusetts by the Boston Globe in 2017 and 2018.[6]

In November 2016 the FDA accepted Flexion's New Drug Application for FX006, an extended-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta".[7] In October 2017 Zilretta was approved by the FDA as the first and only extended-release intra-articular therapy for patients confronting osteoarthritis-related knee pain.[8]

In December 2017, Flexion acquired an investigational gene therapy product candidate for the treatment of osteoarthritis (OA), known as FX201.[9] In late 2019, the company initiated a Phase 1 clinical trial evaluating safety and tolerability of FX201 in 15-24 patients. Flexion believes FX201 holds the potential to provide extended relief from OA knee pain for at least six to 12 months and modify the disease.[10]

In September 2019, Flexion announced the development of FX301, a locally administered NaV1.7 inhibitor product candidate, known as funapide, formulated for extended release in a thermosensitive hydrogel. The initial development of FX301 is intended to support administration as a peripheral nerve block for control of post-operative pain. Flexion believes FX301 has the potential to provide effective pain relief while preserving motor function and anticipates initiating clinical trials in 2021.[11][12]

References
  1. Gormley, Brian. (28 November 2011). "Flexion Changes Endgame, Advances Osteoarthritis Drugs." Dow Jones VentureWire.
  2. Young, Robin (March 8, 2012). "Could This Be Orthopedics' Future?". Orthopedics This Week. Archived from the original on May 14, 2012.
  3. "How Flexion Pivoted To Become A Commercial Biotech". www.clinicalleader.com. Retrieved 2021-02-09.
  4. Weisman, Robert (December 12, 2016). "2 biotechs look to market knee pain treatments - The Boston Globe". Boston Globe.
  5. Inc, Flexion Therapeutics (2019-06-20). "Flexion Therapeutics Named one of Boston Business Journal's Best Places to Work for the Third Consecutive Year". GlobeNewswire News Room. Retrieved 2021-02-09.
  6. Inc, Flexion Therapeutics (2018-11-16). "Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe". GlobeNewswire News Room. Retrieved 2021-02-09.
  7. "Triamcinolone acetonide sustained-release". AdisInsight. Retrieved 17 July 2017.
  8. Inc, Flexion Therapeutics (2017-10-06). "Flexion Therapeutics Announces FDA Approval of Zilretta™ (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis (OA) Knee Pain". GlobeNewswire News Room. Retrieved 2020-01-24.
  9. "Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee". www.bloomberg.com. Retrieved 2020-01-24.
  10. Flexion Therapeutics, Inc. (2020-09-16). "An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients With Osteoarthritis of the Knee". {{cite journal}}: Cite journal requires |journal= (help)
  11. "Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion's Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain". BioSpace. Retrieved 2020-01-24.
  12. Inc, Flexion Therapeutics (2020-04-27). "Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain". GlobeNewswire News Room. Retrieved 2021-02-09.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.